| Literature DB >> 19438641 |
G Yang1, R Benson, T Pelish, E Brown, J M Winchell, B Fields.
Abstract
Although the majority of cases of Legionnaires' disease (LD) are caused by Legionella pneumophila, an increasing number of other Legionella species have been reported to cause human disease. There are no clinical presentations unique to LD and hence accurate laboratory tests are required for early diagnosis. Therefore, we designed a real-time PCR assay that targets the 23S-5S rRNA intergenic spacer region (23S-5S PCR) and allows for detection of all Legionella species and discrimination of L. pneumophila from other Legionella species. In total, 271 isolates representing 50 Legionella species were tested and the assay was validated using 39 culture-positive and 110 culture-negative patient specimens collected between 1989 and 2006. PCR-positive results were obtained with all 39 culture-positive samples (100% sensitivity). Specimens that tested positive according to 23S-5S PCR, but were culture-negative, were further analysed by DNA sequencing of the amplicon or the macrophage infectivity potentiator (mip) gene. In addition to L. pneumophila, Legionella longbeachae, Legionella cincinnatiensis and Legionella micdadei were identified in the specimens. The assay showed a 7-log dynamic range displaying a sensitivity of 7.5 CFU/mL or three genome equivalents per reaction. Sixty-one specimens containing viruses or bacteria other than Legionellae were negative according to 23S-5S PCR, demonstrating its specificity. Use of this assay should contribute to the earlier detection of respiratory disease caused by Legionella species, as well as to increased rates of detection.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19438641 PMCID: PMC7129662 DOI: 10.1111/j.1469-0691.2009.02766.x
Source DB: PubMed Journal: Clin Microbiol Infect ISSN: 1198-743X Impact factor: 8.067
Clinical specimens for validating 23S‐5S assay
| Sample type | Cultures positive (+), | PCR positive (+), | PCR negative (−), | Cultures (−)/PCR (+), | Total | |
|---|---|---|---|---|---|---|
| Sputum | 9 | 18 | 40 | 9 | 58 | |
| Lung tissue | 24 | 31 | 28 | 7 | 59 | |
| Bronchoalveolar lavage | 2 | 3 | 4 | 1 | 7 | |
| Bronchial swab | 2 | 2 | 0 | 0 | Not applicable | 2 |
| Nasopharyngeal swab | 2 | 2 | 0 | 0 | Not applicable | 2 |
| Blood | 0 | 8 | 0 | 8 | 8 | |
| Liver | 0 | 0 | 1 | 0 | Not applicable | 1 |
| Trans‐tracheal aspirate | 0 | 0 | 1 | 0 | Not applicable | 1 |
| Spleen | 0 | 0 | 1 | 0 | Not applicable | 1 |
| Pleural fluid | 0 | 1 | 1 | 1 | 2 | |
| Formalin‐fixed and paraffin embedded tissue (FFPE) | 0 | 1 | 7 | 1 | 8 | |
| Total number of specimens | 39 | 66 | 83 | 27 | 27 | 149 |
| Percentage of specimens | 26% | 44% | 56% | 18% | 18% | 100.0% |
mip sequence analysis for all culture−/PCR+ samples unless otherwise indicated.
No sample left for sequencing.
Not applicable for sequence analysis.
Amplicon sequence analysis only.
Positive for Legionella pneumophila.
FIG. 1Assay design and standard curve analysis. (a) Schematic diagram of the design of the primers and probes. The forward/reverse primers were selected in the 23S-5S intergenetic region conserved for all Legionella spp. Two TaqMan probes were designed in the antisense strand of the amplicon. One probe recognized all Legionella spp. and the other was Legionella pneumophila-specific. Both probes are quenched at the 3'-end by black hole quencher (BHQ), but labelled by different fluorescent reporter molecules with distinct emission wavelength. (b) Real-time PCR standard curves generated from L. pneumophila probe (upper panel) and Legionella spp. probe (lower panel). Seven ten-fold serial dilutions of Legionella genomic DNA were prepared for qPCR. The concentration of genomic DNA for each dilution ranged from 3 gEq to 3.0 E + 6 gEq per PCR reaction. The standard curve equation, R2 value, and amplification efficiency are indicated. (c) Gel analysis of the endpoint PCR product. The amplicon derived from the PCR reaction that has the highest amount of the template (3.0 E + 6 gEq) was analysed on 4% E-gel (Invitrogen Corp., Carlsbad, CA, USA) to assess amplification specificity. Lane 1: 25-bp DNA ladder (Promega Corp., Madison, WI, USA). gEq, genome equivalent; Ct, cycle threshold.
Legionella species used for evaluating the 23S‐5S assay
| Strains, | ||
|---|---|---|
| 1 | 66 | |
| 2 | 1 | |
| 3 | 18 | |
| 4 | 1 | |
| 5 | 5 | |
| 6 | 31 | |
| 7 | 1 | |
| 8 | 1 | |
| 9 | 3 | |
| 10 | 3 | |
| 11 | 2 | |
| 12 | 7 | |
| 13 | 3 | |
| 14 | 1 | |
| 15 | 2 | |
| 16 | 7 | |
| 17 | 1 | |
| 18 | 1 | |
| 19 | 4 | |
| 20 | 1 | |
| 21 | 1 | |
| 22 | 4 | |
| 23 | 1 | |
| 24 | 2 | |
| 25 | 2 | |
| 26 | 2 | |
| 27 | 7 | |
| 28 | 2 | |
| 29 | 1 | |
| 30 | 1 | |
| 31 | 6 | |
| 32 | 1 | |
| 33 | 2 | |
| 34 | 3 | |
| 35 | 3 | |
| 36 | 2 | |
| 37 | 3 | |
| 38 | 8 | |
| 39 | 2 | |
| 40 | 3 | |
| 41 | 6 | |
| 42 | 1 | |
| 43 | 3 | |
| 44 | 3 | |
| 45 | 1 | |
| 46 | 2 | |
| 47 | 4 | |
| 48 | 2 | |
| 49 | 1 | |
| 50 | 2 | |
| Unidentified | 31 | |
| Total | 271 | |